ІМУНОТЕРАПІЯ РАКУ ШЛУНКА. НОВІ ДАНІ

Автор(и)

  • R. W. Senjutovich ВДНЗ України “Буковинський державний медичний університет”, м. Чернівці, Україна
  • O. I. Ivaschuk ВДНЗ України “Буковинський державний медичний університет”, м. Чернівці, Україна
  • V. U. Bodiaka ВДНЗ України “Буковинський державний медичний університет”, м. Чернівці, Україна
  • T. V. Kruk ВДНЗ України “Буковинський державний медичний університет”, м. Чернівці, Україна
  • N. V. Zelinska ВДНЗ України “Буковинський державний медичний університет”, м. Чернівці, Україна
  • O. B. Chornyi Прикарпатський національний університет ім. В. Стефаника, Україна
  • V. M. Pylypiv Прикарпатський національний університет ім. В. Стефаника, Україна
  • M. A. Senjutovich ВДНЗ України “Буковинський державний медичний університет”, м. Чернівці, Україна

DOI:

https://doi.org/10.24061/1727-4338.XIV.4.54.2015.49

Ключові слова:

рак, шлунок, імунотерапія

Анотація

Представлений огляд літератури 2012-2014рр. з імунотерапії раку шлунка. У поодиноких клінічних дослідженнях показано продовження виживання хворих при поширених раках шлунка на 2-4 місяці. Метод не вийшов з стадії клінічного експерименту.

Посилання

Celluzzi CM, Mayordomo Jl, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. Journal of Experimental Medicine. 1996;183(l):83-287.

Gilboa E. DC-based cancer vaccines. Journal of Clinical Investigation. 2007;117(5):1195-1203.

Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with. Clinical Cancer Research. 2002;8(11):3394-3400.

Orange JS, Balias ZK. Clinical Immunology. Natural killer cells in human health and disease. 2006;118(1):1-10.

June CH. Principles of adoptive T cell cancer therapy. Journal of Clinical Investigation. 2007;117(5):1204-12.

Kim JH, Kang TH, Noh KH, et al. Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN. Immunology Letters. 2010;134(1):47-54.

Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined withautologous cytokine-induced killer cells. Anticancer Research. 2006;26(3):2237-42.

Amedei A, Benagiano M, Bella C, et al. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol. 2011;12(4):4373- 78.

Kim YJ, Lim J, Kang JS, et al. Adoptive immunotherapy of human gastric cancer with ex vivo expanded TA cells. Cancer Letters. 2010;33(11):1789-95.

Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014;20(7):1657-66.

Turcotte S, Gros A, Tran E, et al. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res. 2014;20(2):331-43.

Toomey PG, Vohra NA, Ghansah T, et al. Immunotherapy for gastrointestinal malignancies. Cancer Control. 2013;20(1);32-42.

Ina K, Kataoka T, Ando T. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem. 2013;13(5):681-88.

Zhao TT, Fan NN, Lin L, et al. Development of therapeutic antibodies for gastric and colorectal cancers. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2012;41(3):345-52.

Tewari M, Sahai S, Mishra RR, et al. Dendritic cell therapy in advanced gastric cancer: a promising new hope. Surg Oncol. 2012;21(3):164-71.

Du XH, Xu YX, Chen L, et al. Treatment pattern of adoptive transfer of immune cells and its application in perioperative period for advanced gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16(1):15-27.

Li Q, Chen J, Liu Y, et al. Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters. Oncol Rep. 2013;30(3):1215-22.

Tian WY, Chen WC, Li R, et al. Markers CD 40, VEGF, AKT, PI3K, and SI00 correlate with tumor stage in gastric cancer. Onkologie. 2013;36(1-2):26-31.

Song J, Ren H, Li Y, et al. rG17PE38, a novel immunotoxin target to gastric cancer with overexpressed CCK-2R. J Drug Target. 2013;21(4):375-82.

Wang L, Chang EW, Wong SC, et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol. 2013;190(2):794-804.

Chen LJ, Zheng X, Shen YP, et al. Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer. Cancer Immunol Immunother. 2013;62(3):553-61.

Fedele C, Carvalho S, Riccio G, et al. Effects of a human compact anti-ErbB2 antibody on gastric cancel. Gastric Cancer. 2014;17(1):107-15.

Tian Y, Jia X, Wang S, et al. SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predictimmunotherapy responsiveness. J Cancer Res Clin Oncol. 2014;140(7):1117-24.

Mao C, Mou X, Zhou Y, et al. Tumor-activated TCRyd(+) cells from gastric cancer patients induce the antitumor immune response of TCRyd T cells via their antigen-presenting cell-like eftects. J. Immunol Res. 2014;59(3):562.

Lin H, Wu X, Wang S, et al. In vitro repolarized tumor macrophages inhibit gastric tumor growth. Oncol Res. 2013;20(7):275-280.

Zhang L, Hou Y, Zhang J, et al. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett. 2013;5(6):1826-32.

Qu J, Hou Z, Han Q, et al. Intracellular poly initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions. J Interferon Cytokine Res. 2014;34(1):52-9.

Gang Y, Zhang X, He Y, et al. Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide. Biochem Cell Biol. 2012;90(6):701-08.

Du X, Jin R, Ning N, et al. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Oncol Rep. 2012;28(5):1743-49.

Liu H, Song J, Ya Z, et al. Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery. Exp Ther Med. 2013;6(4):953-56.

Wang ZM, Zhuang RY, Chen Y, et al. A pilot study of chemotherapy combined with intraperitoneal perfusion of cytokine-induced killer cells for advanced gastric cancer patients with ascites. Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16(1):28-31.

Zhao H, Fan Y, Li H, et al. Immunotherapy with Cytokine-Induced Killer Cells as an Adjuvant Treatment for Advanced Gastric Carcinoma: A Retrospective Study of 165 Patients. Cancer Biother Radiopharm. 2013;18(4):145-68.

Ishigami S, Natsugoe S, Uenosono Y, et al. Infiltration of antitumor immunocytes into the sentinel node in gastric cancer. Journal of Gastrointestinal Surger. 2003;7(6):735-39.

Cidon EU, Ellis SG, lnam Y, et al. Molecular targeted agents for gastric cancer: a step torwau towards personalized therapy. Cancers (Basel). 2013;5(1):64-91.

Ahn MS, Kang SY, Lee HW, et al. 5-Fluorouracil, mitomycin-c, and polysaccharide-k versi uracil-ftoratur and polysaccharide-K as adjuvant chemoimmunotherapy fc patients with locally advanced gastric cancer with curative resection. Onkologie. 2013;36(7-8):421-26.

Tanaka H, Muguruma K, Ohira M, et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer Res. 2012;32(8):3427-33.

Ishigami S, Natsugoe S, Tokuda K, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Letters. 2000;159(1):103-08.

Shi L, Zhou Q, Wu J, et al. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunol Immunother. 2012;61(12):2251-59.

Saito M, Yano K, Kamigaki T, et al. A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA). Anticancer Res. 2013;33(7):2957-63.

Marano L, Porfidia R, Pezzella M, et al. Clinical and immunological impact of early postoperative enteral immunonutrition after total gastrectomy in gastric cancel patients, a prospective randomized study. Ann Surg Oncol. 2013;20(12):3912-18.

Fujitani K., Tsujinaka T, Fujita J, et al. Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer. Br J Surg. 2012;99(5):621-29.

##submission.downloads##

Опубліковано

2017-04-07

Номер

Розділ

Статті